Compare SNGX & AEHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | AEHL |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Materials |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 8.6M |
| IPO Year | 2006 | 2009 |
| Metric | SNGX | AEHL |
|---|---|---|
| Price | $0.36 | $7.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 104.9K | ★ 581.2K |
| Earning Date | 11-10-2026 | 07-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,371.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.27 |
| 52 Week High | $3.39 | $30.60 |
| Indicator | SNGX | AEHL |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 42.55 |
| Support Level | $0.32 | $0.83 |
| Resistance Level | $0.82 | $7.40 |
| Average True Range (ATR) | 0.02 | 2.89 |
| MACD | 0.01 | -0.42 |
| Stochastic Oscillator | 64.02 | 0.22 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Antelope Enterprise Holdings Ltd operates in three reportable operating segments: Business Management Consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting; Natural Gas Power generation, which was in the initial development stage; and Live-Streaming e-commerce segment, providing a one-stop solution for customers to enable them to utilize the growing sales channel of livestreaming ecommerce. The business of the Company is engaged in the PRC and the United States.